Evidence map›Paper›PMID 38638855›Full record

ReviewFrontiers in oncology2024

Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.

Mariusz A Wasik, Patricia M Kim, Reza Nejati

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mariusz A WasikDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, United States.
Patricia M KimDepartment of Pathology and Laboratory Medicine, Penn State College of Medicine, Hershey, PA, United States.
Reza NejatiDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, PA, United States.
Fox Chase Cancer Center · USPennsylvania State University · US

Funding

Metabolic Imaging of Targeted Therapies in CancerR01CA268601 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Kavindra Nath, MARIUSZ A. WASIK · 2022 to 2026
$3.0M
Melanoma: Metabolic Biomarkers of Response to Targeted TherapyR01CA250102 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER, NATH, KAVINDRA · 2020 to 2024
$2.4M
NCI NIH HHS R01 CA250102NCI NIH HHS R01 CA268601
6 · The paper itself

Abstract

While normal B- and T-lymphocytes require antigenic ligands to become activated via their B- and T-cell receptors (BCR and TCR, respectively), B- and T-cell lymphomas show the broad spectrum of cell activation mechanisms regarding their dependence on BCR or TCR signaling, including loss of such dependence. These mechanisms are generally better understood and characterized for B-cell than for T-cell lymphomas. While some lymphomas, particularly the indolent, low-grade ones remain antigen-driven, other retain dependence on activation of their antigen receptors seemingly in an antigen-independent manner with activating mutations of the receptors playing a role. A large group of lymphomas, however, displays complete antigen receptor independence, which can develop gradually, in a stepwise manner or abruptly, through involvement of powerful oncogenes. Whereas some of the lymphomas undergo activating mutations of genes encoding proteins involved in signaling cascades downstream of the antigen-receptors, others employ activation mechanisms capable of substituting for these BCR- or TCR-dependent signaling pathways, including reliance on signaling pathways physiologically activated by cytokines. Finally, lymphomas can develop cell-lineage infidelity and in the extreme cases drastically rewire their cell activation mechanisms and engage receptors and signaling pathways physiologically active in hematopoietic stem cells or non-lymphoid cells. Such profound reprograming may involve partial cell dedifferentiation or transdifferentiation towards histocytes, dendritic, or mesodermal cells with various degree of cell maturation along these lineages. In this review, we elaborate on these diverse pathogenic mechanisms underlying cell plasticity and signaling reprogramming as well as discuss the related diagnostic and therapeutic implications and challenges.

Indexed as

B-cell lymphomadedifferentiationpathogenic signaling plasticityT-cell lymphomatransdifferentiation

Identifiers

PMID38638855
PMCPMC11024630
OpenAlexW4393943232

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.